loading page

Peptidylglycine α-amidating monooxygenase as a therapeutic target or biomarker
  • +1
  • David Merkler,
  • Aidan Hawley,
  • Betty Eipper,
  • Richard Mains
David Merkler
University of South Florida

Corresponding Author:[email protected]

Author Profile
Aidan Hawley
University of South Florida
Author Profile
Betty Eipper
UConn Health Center
Author Profile
Richard Mains
UConn Health Center
Author Profile


Peptides play a key role in controlling many physiological and neurobiological pathways. Many bioactive peptides require a C-terminal α-amide for full activity. The bifunctional enzyme catalyzing α-amidation, peptidylglycine α-amidating monooxygenase (PAM), is the sole enzyme responsible for amidated peptide biosynthesis, from Chlamydomonas reinhardtii to Homo sapiens. Many neuronal and endocrine functions are dependent upon amidated peptides; additional amidated peptides are growth promoters in tumors. The amidation reaction occurs in two steps, glycine α-hydroxylation followed by dealkylation to generate the α-amide product. Currently, most potentially useful inhibitors target the first reaction, which is rate-limiting. PAM is a membrane-bound enzyme that visits the cell surface during peptide secretion. PAM is then used again in the biosynthetic pathway, meaning that cell-impermeable inhibitors or inactivators could have therapeutic value for the treatment of cancer or psychiatric abnormalities. To date, inhibitor design has not fully exploited the structures and mechanistic details of PAM.
23 Jun 2021Submitted to British Journal of Pharmacology
23 Jun 2021Submission Checks Completed
23 Jun 2021Assigned to Editor
28 Jul 2021Reviewer(s) Assigned
10 Dec 2021Review(s) Completed, Editorial Evaluation Pending
12 Dec 2021Editorial Decision: Revise Minor
09 Jan 20221st Revision Received
11 Jan 2022Submission Checks Completed
11 Jan 2022Assigned to Editor
12 Jan 2022Editorial Decision: Accept
06 Feb 2022Published in British Journal of Pharmacology. 10.1111/bph.15815